UCal granted wide-ranging CRISPR rights, but future patent landscape remains uncertain
Despite doubts, the University of California has been awarded fundamental rights to Cas9 gene-editing technology. But validity challenges could be on the way, experts say.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.